Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Cureus|March 2, 2026
Hereditary Hyperferritinemia-Cataract Syndrome Misdiagnosed as Iron Overload: A Case ReportSerkan Güven, Menekse ÖztürkInternational Journal of Molecular Sciences|March 6, 2021
Does a Red House Affect Rhythms in Mice with a Corrupted Circadian System?Menekse Öztürk, Marc Ingenwerth, Martin Sager, et al.Neurological Research and Practice|August 23, 2023
Introducing electronic monitoring of disease activity in patients with chronic inflammatory demyelinating polyneuropathy (EMDA CIDP): trial protocol of a proof of concept studyLars Masanneck, Jan Voth, Niklas Huntemann, et al.Journal of Cachexia, Sarcopenia and Muscle|June 1, 2026
Longitudinal Assessment of Muscle Involvement in Late-Onset Pompe Disease Using Quantitative MRI: A Prospective Cohort StudyAlice De Lorenzo, Johannes Forsting, Martijn Froeling, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|June 30, 2025
CD19xCD3 T cell engager blinatumomab effective in refractory generalized myasthenic syndromesTobias Ruck, Niklas Huntemann, Menekse Öztürk, et al.Annals of Neurology|November 26, 2024
Increased Disability Progression in rs10191329<sup>AA</sup> Carriers with Multiple Sclerosis Is Preceded by Neurofilament Light Chain ElevationsMaria Protopapa, Falk Steffen, Muriel Schraad, et al.Journal of Neuroinflammation|April 13, 2022
Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patientsChristopher Nelke, Frauke Stascheit, Carmen Eckert, et al.Cells|April 11, 2025
Effects of Anti-CD20 Antibody Therapy on Immune Cell Dynamics in Relapsing-Remitting Multiple SclerosisAlice G Willison, Ramona Hagler, Margit Weise, et al.Journal of Neurology, Neurosurgery, and Psychiatry|March 5, 2022
Eculizumab versus rituximab in generalised myasthenia gravisChristopher Nelke, Christina B Schroeter, Frauke Stascheit, et al.Journal of Neurology, Neurosurgery, and Psychiatry|January 11, 2025
C5 complement inhibition versus FcRn modulation in generalised myasthenia gravisNiklas Huntemann, Lea Gerischer, Meret Herdick, et al.Pageof 2